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Abstract
Background: Greece has the highest proportion of smokers in the European Union with 42% of Greeks admitting
that they smoke, based on a 2009 survey. This post-hoc analysis of a prospective, observational study evaluated the
effectiveness and safety profile of the smoking cessation aid varenicline, as well as potential predictors of quit
success in a Greek population.
Methods: Participants were prescribed varenicline according to the recommendations of the European Summary
of Product Characteristics (1 mg twice daily). The 7-day point prevalence of abstinence at Week 12 was determined
based on verbal reporting using a nicotine use inventory. Abstinence was confirmed by carbon monoxide
measurements of exhaled air at the last visit of the study. The safety profile of varenicline was also assessed.
Results: At baseline, the Greek subsample (n = 196) had a mean age of 42.6 years, with 54.6% of them being men.
Participants had a smoking history of 23.5 years and a Fagerström Test for Nicotine Dependence total score of 6.6.
After 12 weeks of varenicline therapy, 70.4% (95% CI, 64.0-76.7) of all participants had quit smoking. This increased
to 86.2% among participants who had taken the study medication for 80% of the planned number of treatment
days. Age was a significant predictor of quit success. The most frequently observed treatment-emergent adverse
event was nausea, occurring in 13.3% of participants.
Conclusions: In this ‘real-world’ observational study, 70.4% of Greek smokers successfully quit smoking after 12
weeks of varenicline therapy, providing support that varenicline is an effective smoking cessation medication.
Further studies with longer follow-up are warranted.
Trial Registration: ClinicalTrials.gov: NCT00669240
Keywords: smoking cessation, Greece, varenicline, real world, observational
Introduction
Tobacco use accounts for over half a million deaths
each year in the European Union (EU), with comprehen-
sive public health policies currently being developed to
curb this epidemic in member countries [1]. Smoking
cessation is a key element of these EU-wide policies.
However, the success rate of quit attempts without
pharmacological assistance is low: only 3-5% of self-quit-
ters remain abstinent after 6-12 months following a quit
attempt [2]. Current guidelines recommend the use of
smoking cessation medications combined with beha-
vioural support to address tobacco dependency and
improve abstinence rates following a quit attempt [3].
Varenicline is among the first-line smoking cessation
aids recommended in the Clinical Practice Guidelines by
the United States Public Health Service [3]. A partial
agonist of the nicotinic a4b2 receptor, it is believed to
reduce nicotine withdrawal symptoms by maintaining
moderate dopamine levels and diminishing smoking
satisfaction [4]. Its efficacy and safety has been demon-
strated in several randomized, double-blind, placebo-
controlled clinical trials [5-10]. Furthermore, a meta-
analysis of various pharmacological interventions for
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smoking cessation found varenicline to be superior to
bupropion and placebo as a smoking cessation aid [11].
In post-marketing surveillance, there have been
reports of psychiatric adverse events. However, a pooled
quantitative safety analysis of 10 randomized, double-
blind, placebo-controlled clinical trials of varenicline in
participants without psychiatric disease found no signifi-
cant association between psychiatric adverse events and
varenicline use, with the exception of sleep disorders
and disturbances [12].
Stringent inclusion and exclusion criteria applied in
randomized, controlled trials mean that participants
with chronic comorbidities or on medication are
excluded. The value of observational studies lies in the
heterogeneity of participants who are included, making
the findings of observational studies more representative
of the general population compared with randomized,
controlled trials.
The CHampix Observational Investigation in the Ces-
sation of Smoking (CHOICES) study investigated vareni-
cline as a smoking cessation aid in routine clinical
practice in four European countries (Belgium, Greece,
Hungary and Slovenia): a self-reported point prevalence
of abstinence of 64.6% after 12 weeks of treatment with
varenicline was reported [13].
Greece has the highest proportion of smokers in the
EU and among member countries of the Organisation
for Economic Cooperation and Development: in a 2009
survey on tobacco use in European countries, 42% of
Greek respondents admitted that they smoke [1,14].
Smoking-related diseases kill approximately 20,000 peo-
ple a year in Greece, costing the country an annual
€2.14 billion (£1.8 billion), according to a statement by
the Greek Health Ministry in 2009 [15,16]. This subana-
lysis of the CHOICES study was conducted to evaluate
the real-life effectiveness and safety profile of varenicline
in a Greek population.
Methods
Study design and participants
The CHOICES study was a 12-week, prospective, obser-
vational, non-comparative trial with 551 participants
conducted in four European countries (Belgium, Greece,
Hungary and Slovenia) between 21 November 2007 and
3 August 2009 [13]. In this post-hoc analysis, only
results from the 196 participants recruited at 10 study
centres in Greece are presented.
The final protocol, any amendments, and informed
consent documentation were reviewed and approved by
the Independent Ethics Committee at each of the inves-
tigational centers participating in the study. This study
was conducted in compliance with the ethical principles
originating in or derived from the Declaration of Hel-
sinki and in compliance with the Independent Ethics
Committees, informed consent regulations, and gener-
ally accepted research practices such as the Good Phar-
macoepidemiology Practices issued by the International
Society for Pharmacoepidemiology.
Participants were eligible for inclusion in the study if
they were adults of legal age who smoked regularly,
with the main tobacco product smoked being cigarettes,
who were willing to make an attempt to stop smoking,
were deemed to be suitable for varenicline treatment
and motivated to quit in the judgement of their super-
vising physician.
Study visits occurred at enrolment and Week 12.
Interim visits were permitted if they were part of a
study site’s normal practice for smoking cessation.
At enrollment, all demographic data (including age
and body mass index [BMI; defined as body weight mea-
sured in kilograms divided by the square of height mea-
sured in meters]), smoking history, nicotine dependence
and smoking-related illnesses were recorded.
Varenicline was administered in accordance with the
European Summary of Product Characteristics (SmPC)
[17] stating that: (i) varenicline treatment should com-
mence 1-2 weeks before the quit date; (ii) for the first 3
days, varenicline should be administered as 0.5 mg once
daily, then uptitrated to 0.5 mg twice daily on Days 4-7;
from Day 8 to the end of the 12-week treatment phase
varenicline should be administered as 1 mg twice daily.
Behavioural support was available to participants
according to the site’s usual practice (e.g., counselling:
reinforcement and discussion about withdrawal pro-
blems in follow-up visits [visit time 15-30 minutes]).
Prior and concomitant medications and comorbidities
There were no restrictions on prior (i.e., before start of
study treatment) and concomitant (i.e., during the study
treatment period) medications or comorbidities apart




The use of nicotine during the 7-day period between
Weeks 11 and 12 (7-day point prevalence of abstinence
[7-day PPA]) was recorded based on verbal reporting
using a nicotine use inventory (NUI) to determine the
smoking status of the participant. The NUI consisted of
the following two questions: whether the person had
smoked “any cigarettes (even a puff)” and “any other
tobacco products (eg, pipe, cigars, snuff, chew)”.
Fagerström Test of Nicotine Dependence
Nicotine dependence was assessed at enrolment using
the Fagerström Test of Nicotine Dependence (FTND),
which consists of six questions [18]. Question 1 of the
FTND read as follows: “How soon after you wake up do
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you smoke your first cigarette?” A total score was calcu-
lated as a sum of the six questions, with lower scores
indicating lower dependence on nicotine: 0-2, very low
dependence; 3-4, low dependence; 5, medium depen-
dence; 6-7, high dependence; and 8-10, very high depen-
dence. Exhaled carbon monoxide was measured at each
visit. Abstinence was confirmed by carbon monoxide
measurements of exhaled air at the last visit of the
study.
Safety evaluations
To assess safety and tolerability of varenicline, investiga-
tors recorded all observed or participant-reported
adverse events, including their opinion regarding the
adverse event intensity (mild [did not interfere with par-
ticipant’s usual function], moderate [interferes to some
extent with participant’s usual function], or severe
[interferes significantly with participant’s usual func-
tion]), as well as the investigators’ expert medical opi-
nions on the relationship of the adverse events to the
study treatment. These adverse events were coded using
the Medical Dictionary for Regulatory Activities (Med-
DRA), version 12. For all adverse events, the investiga-
tors determined both the adverse event outcome, as well
as whether any specific adverse events met the criteria
for classification as a serious adverse event. A serious
adverse event was defined as any adverse event that was
life-threatening; caused death; resulted in new, or pro-
longation of existing, in-patient hospitalisation; led to a
persistent or significant disability/incapacity; resulted in
a congenital anomaly/birth defect; or if they required
medical or surgical intervention to prevent one of these
outcomes listed. Moreover, serious adverse events could
also include any adverse event that the sponsor or inves-
tigators considered serious enough to be classified as
such. Safety data were collected and assessed using the
same procedures and standards as in previous clinical
trials of varenicline.
Statistical analysis
The analysis included all enrolled participants in Greece
who had received at least one dose of study medication.
Descriptive summaries were provided as counts and per-
centages for categorical variables and as means and
standard deviations for continuous variables. Exact
Clopper-Pearson 95% confidence limits for the absti-
nence rates were determined based on the binomial
distribution.
7-day PPA by baseline age, baseline FTND total score
and by baseline FTND Question 1 response (ie, time to
first cigarette on waking) were analyzed using univariate
logistic regression models to compare groups. The ana-
lyses were performed using SAS version 9.2.
Results
Demographics and smoking history
In total, 196 Greek smokers received varenicline in this
study. Their mean age was 42.6 years, with 54.6% of
them being men (Table 1). The mean duration of smok-
ing was 23.5 years, with a mean number of 29.7 cigar-
ettes being smoked per day. The total FTND score was
6.6 for this population, indicating a high dependence on
nicotine, with most participants (42.1%) smoking
between 21 and 30 cigarettes per day (Table 1).
Prior and concomitant medications and comorbidities
The most frequently used prior and concomitant medi-
cations were aspirin (9 out of 53 [17.0%]), levothyroxine
sodium (8 out of 53 [15.1%]) and atorvastatin (6 out of
53 [11.3%]). The most frequently observed comorbidities
were hypertension (16.8%), chronic obstructive pulmon-
ary disease (8.2%) and depression (7.1%) (Table 2).
Compliance and duration of treatment exposure
Overall, 40 (20.4%) Greek participants in this subanalysis
discontinued from the study: 16 (8.2%) due to study
drug (adverse events, 5 [2.6%]; and lack of efficacy, 11
[5.6%]) and 24 (12.2%) for reasons that were unrelated
to study drug (lost to follow-up, 6 [3.1%]; subject no
longer willing to participate in this study, 16 [8.2%];
other, 2 [1.0%]). The median duration of treatment was














BMI, kg/m2 (SD) 28.3 (4.6) 24.0 (4.2) 26.3 (4.9)
Medical history related to smoking, mean (SD)
Total number of years smoked 25.1 (10.8) 21.4 (8.4) 23.5 (10.0)
Mean number of cigarettes per
day
32.5 (15.5) 26.2 (11.9) 29.7 (14.3)
Severity of smoking, n (%)
≤ 10 cigarettes/day 0 (0.0) 6 (7.0) 6 (3.1)
11-20 cigarettes/day 23 (21.4) 26 (30.5) 49 (25.5)
21-30 cigarettes/day 45 (42.0) 36 (42.3) 81 (42.1)
> 30 cigarettes/day 39 (36.4) 17 (20.0) 56 (29.1)
FTND total score 6.7 (2.2) 6.4 (2.3) 6.6 (2.2)
FTND question 1 response, n (%)
< 5 mins 45 (42.0) 41 (48.2) 86 (44.7)
5-30 mins 40 (37.3) 26 (30.5) 66 (34.3)
31-60 mins 13 (12.1) 15 (17.6) 28 (14.5)
> 60 mins 9 (8.4) 3 (3.5) 12 (6.2)
BMI, body mass index; SD, standard deviation; FTND, Fagerström Test of
Nicotine Dependence
* n = 4 with unspecified gender; n/a, not available.
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84.0 days, with 39.7% of participants taking varenicline
for 61-90 days.
Outcomes
By the end of the 12-week treatment period, 70.4% (95%
confidence interval [C.I.] 64.0-76.7) of all participants
had quit smoking (Figure 1). The rate of abstinence
increased with better compliance. We considered as
‘completers’ those participants who had a good treat-
ment compliance defined as taking study medication for
80% of the planned number of treatment days. A total
of 119 of 138 (86.2%) smokers who were characterized
as completers had quit smoking by Week 12 (Figure 1).
Furthermore, abstinence increased significantly with
increasing age (Figure 2).
When the relationship between successful smoking
cessation and the FTND total score were investigated, it
was found that in participants with a total FTND score
of > 7, 62.0% had successfully quit smoking at Week 12
(Figure 3). In participants with a lower dependence on
nicotine (ie, an FTND score of ≤ 7), the quit rate was
even higher (ie, 75.0%) (Figure 3). However, there was
no statistically significant difference between these quit
rates (p = 0.057), therefore the FTND total score was
not predictive of successful smoking cessation in this
analysis although the results approached significance.
Figure 1 Success rates for smoking cessation in the self-
reported 7-day period between Weeks 11 and 12 (7-day point
prevalence of abstinence). All participants, all enrolled participants
who had received at least 1 dose of study medication (either
morning, evening or both of the planned twice-daily doses);
evaluable participants, participants who took at least 14 days of
study medication in the first 21 days (a day of study medication
being defined as a calendar day during which the participant
received any dose of study medication); completers, participants
with at least 80% of treatment compliance defined as having any
dose of study medication for 80% of the planned number of
treatment days.
Figure 2 Self-reported 7-day point prevalence of abstinence at
Week 12 in Greek participants of the CHOICES study by
baseline age. Age was unknown for 4 participants. p = 0.035 for
overall age group differences based on univariate logistic regression
model.
Figure 3 Self-reported 7-day point prevalence of abstinence at
Week 12 in Greek participants of the CHOICES study by
baseline nicotine dependence as assessed by the FTND total
score. The FTND total score was not available for 2 participants.
These 2 individuals were excluded from this analysis. Based on
univariate logistic regression model.
Table 2 Comorbidities occurring in ≥2% of participants
Hypertension, n (%) 33 (16.8)
Chronic obstructive pulmonary disease, n (%) 16 (8.2)
Depression, n (%) 14 (7.1)
Diabetes mellitus, n (%) 11 (5.6)
Hypothyroidism, n (%) 8 (4.1)
Asthma, n (%) 8 (4.1)
Epilepsy, n (%) 6 (3.1)
Migraine, n (%) 4 (2.0)
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Likewise, there was no statistically significant relation-
ship between successful smoking cessation and the
severity of smoking at baseline (p = 0.399) and between
abstinence and gender (p = 0.567).
The relationship between successful smoking cessation
and Question 1 of the FTND ("How soon after you
wake up do you smoke your first cigarette?”) was also
investigated using logistic regression models. There was
a trend, albeit not statistically significant, for decreased
odds of success with decreasing time to the first cigar-
ette within 60 minutes after waking up (Figure 4).
Safety/tolerability
The most frequently observed treatment-emergent
adverse events (all-causality) were nausea (13.3%),
insomnia (4.6%) and upper abdominal pain (4.1%),
mostly of mild to moderate intensity (Table 3). These
adverse events are already listed in the SmPC [17]. The
most frequent psychiatric disorders were insomnia
(4.6%), abnormal dreams (3.6%) and nervousness (1.0%).
These symptoms were controlled within 10 days in most
of the participants. No serious adverse events were
observed.
Discussion
The findings of this subanalysis of CHOICES indicate
that a high smoking abstinence was achieved in the
Greek population of this study, despite participants’
heavy dependence on nicotine. This study has shown
that treatment with varenicline as provided by a smok-
ing cessation clinic outside a clinical trial environment
can be very effective as a smoking cessation treatment.
Overall, 70.4% of Greek participants successfully quit
smoking at the end of a 12-week course of varenicline,
as assessed by self-reported 7-day PPA as a measure of
abstinence. Neither the total FTND score nor FTND
Question 1 response (ie, time to first cigarette on wak-
ing) significantly predicted a successful 7-day PPA at
Week 12. The most frequently observed adverse events
were nausea (13.3%), insomnia (4.6%) and upper abdom-
inal pain (4.1%), mostly of mild to moderate severity.
The efficacy and tolerability of varenicline has been
shown in various placebo-controlled, double-blind, ran-
domized clinical trials [11,12]. Stringent inclusion and
exclusion criteria applied in these trials meant that par-
ticipants with chronic comorbidities and medication
were excluded. The value of observational studies, such
as CHOICES, lies in the heterogeneity of participants
who are enrolled, making the findings more representa-
tive of the general population. For example, in the ana-
lysis presented here, a high proportion of participants
had a medical history of hypertension, chronic obstruc-
tive pulmonary disease or depression and had effective
treatment for smoking cessation with varenicline. These
findings support varenicline use in populations with
these comorbidities. This has also been shown in dou-
ble-blind clinical trials [10].
In the main CHOICES study [13] the 7-day PPA by
Week 12 was 64.6% (95% C.I. 60.1-68.3), while 61.1%
was reported for a subanalysis of the Belgian population
enrolled in the CHOICES study[19]. This compares with
a 7-day PPA of 70.4% (95% C.I. 64.0-76.7) for the Greek
population at Week 12 which is reported here. The
higher rate of abstinence in our population may be due
to a number of factors including differences between the
Greek study centres versus the other countries in the
CHOICES trial (Belgium, Hungary and Slovenia), such
as, differences in behavioural support and/or reimburse-
ment. Although these factors were not compared in the
CHOICES trial and a further trial would be required in
order to evaluate the impact of any differences on out-
comes, it is important to note that in Greece this obser-
vational study was carried out in respiratory
departments and smokers were treated and monitored
by the same medical doctor throughout the trial. Doc-
tors had received training in smoking cessation strate-
gies and were voluntarily referred to the smoking
cessation clinics, where behavioural support was pro-
vided. High abstinence rates have been previously
reported in these clinics using other smoking cessation
treatments, such as behavioural support, nicotine repla-
cement products and bupropion SR, in Greek smokers
[20,21].
It is also important to note that at the time the
CHOICES study was conducted, there was no reimbur-
sement policy for smoking cessation medications
Figure 4 Self-reported 7-day point prevalence of abstinence at
Week 12 in Greek participants of the CHOICES study by
baseline FTND Question 1 response ("How soon after you wake
up do you smoke your first cigarette?”). OR = Relative change in
odds for shift to an adjacent category going from longer times to
shorter times based on univariate logistic regression model.
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(including varenicline) in Greece, although there are
current proposals to partially reimburse Greek smokers
for smoking cessation medications in the future.
One additional important finding of the study is the
higher rate of abstinence with better compliance. We
considered as completers those participants who had
good treatment compliance, defined as taking study
medication for 80% of the planned number of treatment
days (more than 8 weeks). 86% of smokers who were
completers had quit smoking by Week 12. This shows
the greater effectiveness of varenicline treatment when it
is taken for more than a month, and indicates that good
compliance to treatment is important and that treat-
ment for more than 8 weeks is associated with higher
success rates. Close follow-up by specialized smoking
cessation clinics increases the compliance to treatment
and further the abstinence rates, as other published stu-
dies in Greek smokers have also reported [20,21].
In the Belgian subanalysis of CHOICES, the FTND
total score was not predictive of successful smoking ces-
sation at Week 12 (P = 0.12; odds ratio [O.R.] 0.65 [95%
C.I. 0.38-1.11]), [22] similar to what is reported here for
the Greek population (P = 0.057; O.R. 0.55 [95% C.I.
0.29-1.02]). The latter was anticipated, as traditional
measures of nicotine dependence, such as the FTND,
are not consistently predictive of successful smoking
cessation, as reported in the literature [23].
Time to first cigarette on waking was predictive of the
7-day PPA at Week 12 in the Belgian subpopulation
[22]. Although there was a similar trend in the Greek
subpopulation, this was not statistically significant (O.R.
0.73, 95% C.I. 0.51-1.06, P = 0.096). This may be so
because the majority of the Greek smokers in this study
belong to the first two categories, lighting up their first
cigarette within the first 30 minutes. In a previously
published study in Greek smokers, multivariate regres-
sion analysis indicated that the time to first cigarette on
waking, and use of bupropion, independently predicted
abstinence [24].
In a recent observational study based on records
stored in The Health Improvement Network (THIN)
database in the United Kingdom, the 7-day PPA 6
months after the initiation of varenicline therapy was
49.5%, based on self-reporting [25]. A longer follow-up
of the participants of the CHOICES study would be of
interest and may give comparable results. A strong and
positive message of this subanalysis of CHOICES is the
high effectiveness of varenicline treatment in Greek
smokers. Unfortunately, in Greece, the smoking ban
laws are not implemented broadly in public places, and
there has been no substantial media campaign support-
ing smoking bans [26].
Conclusions
Despite the heavy smoking history of the Greek partici-
pants in CHOICES and negative public attitudes in
Greece with regard to the indoor public smoking ban,
70% of Greek smokers successfully quit smoking after
12 weeks of varenicline therapy in this ‘real-world’
observational study, providing further support that vare-
nicline is an effective smoking cessation medication.
This suggests that abstinence is not related to the nico-
tine dependence or smoking history of a population.
Personal motivation, intensive support and close follow-
up by specialized smoking cessation clinics may increase
patient compliance and abstinence rates. It should be
noted that this subanalysis is only exploratory in nature,
as the original CHOICES study was not powered to
determine differences between subgroups. The long-
term effectiveness of varenicline based on compliance
and treatment duration and the relapse rate of Greek
smokers would be interesting objectives of future stu-
dies. Thus, further studies with longer follow-up are
warranted.
Table 3 Incidence of treatment-emergent adverse events (all causality) in ≥ 1 participants by intensity









Nausea 26 (13.3) 17 (8.7) 7 (3.6) 2 (1.0)
Insomnia 9 (4.6) 6 (3.1) 2 (1.0) 1 (0.5)
Abdominal pain, upper 8 (4.1) 4 (2.0) 1 (0.5) 3 (1.5)
Abnormal dreams 7 (3.6) 4 (2.0) 3 (1.5) 0 (0.0)
Dry mouth 4 (2.0) 3 (1.5) 1 (0.5) 0 (0.0)
Constipation 3 (1.5) 0 (0.0) 2 (1.0) 1 (0.5)
Nervousness 2 (1.0) 2 (1.0) 0 (0.0) 0 (0.0)
Migraine 2 (1.0) 1 (0.5) 1 (0.5) 0 (0.0)
Somnolence 2 (1.0) 2 (1.0) 0 (0.0) 0 (0.0)
Gastrointestinal disorder 2 (1.0) 2 (1.0) 0 (0.0) 0 (0.0)
Vomiting 2 (1.0) 2 (1.0) 0 (0.0) 0 (0.0)
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